United States Patent 12,036,290: Scope, Claim Coverage, and Landscape
United States Patent 12,036,290 covers a radiohybrid imaging composition built around a silicon-fluoride (Si-F) group coupled to a chelating group, with enforceable claim limits on (i) the identity of the radionuclide or chelated metal, (ii) buffer/solvent/salt composition, and (iii) tight formulation pH and concentration bands. Dependent claims narrow to specific citrate preparation conditions, ethanol and sodium chloride ranges, and specific nuclides including ^18F and ^68Ga.
What is the core inventive concept in the claims?
The independent claim (Claim 1) requires a pharmaceutical composition with these pillars:
1) Radiohybrid agent structure / labels
- A radiohybrid agent that contains:
- a silicon-fluoride group and
- a chelating group
- One of two labeling states applies:
- Option A: the fluorine on the silicon-fluoride group is ^18F, or
- Option B: the chelating group contains a chelated radioactive metal
- The radiohybrid agent is defined as:
- “or an isomer or salt thereof” (broad structural coverage via equivalents in the agent family)
2) Chelated metal specification
- The claim introduces M3+ as “a chelated radioactive or non-radioactive metal.”
3) Formulation constraints (these are not optional)
- The composition has a pH of 4.0 to 6.0
- and further comprises:
- citrate buffer: 0.1 to 200 mM
- ethanol: 1 to 100 mg/mL
- sodium chloride: 5 to 10 mg/mL
This combination is the claim’s practical boundary: infringement requires both the radiohybrid chemistry and the specific formulation regime.
How broad is Claim 1 versus the dependent claims?
Claim 1 (independent): breadth from chemistry, but narrow on formulation
Breadth drivers
- Covers ^18F on the Si-F group OR alternatively a scenario where the chelating group contains a chelated radioactive metal.
- Covers radioactive or non-radioactive M3+.
- Covers “isomer or salt” of the radiohybrid agent.
Narrowness drivers
- Requires the full formulation triad:
- citrate buffer 0.1 to 200 mM
- ethanol 1 to 100 mg/mL
- NaCl 5 to 10 mg/mL
- Locks pH window to 4.0 to 6.0.
Claims 2 to 4: tightening citrate, ethanol, and pH
- Claim 2: citrate buffer 1 to 15 mM
- Claim 3: ethanol 5 to 50 mg/mL
- Claim 4: pH 4.5 to 5.5
Impact
- These dependent claims carve out embodiments that sit inside Claim 1, tightening the formulation space. They matter for design-around risk if a product aims for lower/upper citrate or ethanol or a near-neutral pH.
Claims 5 to 6: citrate buffer preparation method and component mg/mL targets
- Claim 5: citrate buffer prepared from:
- citric acid + sodium hydroxide, OR
- sodium citrate + hydrochloric acid
- Claim 6: specific preparation amounts:
- citric acid 1 to 3 mg/mL
- sodium hydroxide 0.5 to 1.0 mg/mL
Impact
- This is a strong hook for manufacturing/process claims. A formulation can meet Claim 1 compositionally but avoid Claim 5/6 if buffer preparation does not follow these listed source-reactant patterns.
Claims 7 to 10: nuclide and chelated metal identity
- Claim 7: ^19F on Si-F and M3+ chelated (radioactive or non-radioactive not changed from Claim 1 context)
- Claim 8: chelated metal M3+ selected from:
- Sc, Cu, Ga, Y, In, Tb, Ho, Lu, Re, Pb, Bi, Ac, Th, Er
- Claim 9: ^18F on Si-F and M3+ is chelated non-radioactive metal
- Claim 10: if the chelated metal is radioactive, it is a positron-emitting isotope
Impact
- These claims do two things simultaneously:
1) Provide explicit “allowed” metal identities for the chelator family.
2) Split labeling scenarios across ^18F on the Si-F versus radioactive M3+ as the radionuclide.
Claim 11: end-of-synthesis (EOS) radioactive concentration
Impact
- This can be pivotal for process and QC-controlled release specifications. It narrows the infringement window for suppliers and in-house production if their actual EOS concentration is outside the band.
Claims 12 and 14: explicit exemplar formulations
- Claim 12:
- citrate buffer 10 mM
- ethanol 50 mg/mL
- sodium chloride 7.2 mg/mL
- pH 5
- Claim 14: diluted composition:
- citrate 1.1 mM (±10%)
- ethanol 5.3 mg/mL (±10%)
- NaCl 8.8 mg/mL (±10%)
- pH 4.5 to 5.5
Impact
- These create concrete “target boxes” often aligned with real product embodiments. Even if Claim 1 is broad, the existence of these anchored dependent claims signals likely prosecution focus on specific formulations.
Claims 13 and 18: dilution with sodium chloride and manufacturing method
- Claim 13: diluted with sodium chloride solution prior to administration
- Claim 18: method of producing composition:
- prepare formulation with radiohybrid agent + citrate buffer + ethanol
- formulation has:
- pH 4.0 to 6.0
- citrate concentration at least 10 mM
- then dilute citrate concentration with sodium chloride
Impact
- If an operator formulates at high citrate (at least 10 mM) then dilutes via saline before administration, Claim 18 narrows product/process escape routes.
Claims 15 to 17: use claims for cancer/neoangiogenesis
- Claim 15: imaging and/or diagnosing cancer via administering Claim 1 composition
- Claim 16: diagnosis, imaging, or prevention of neoangiogenesis/angiogenesis via administering Claim 1
- Claim 17: specific cancers:
- prostate, breast, lung, colorectal, renal cell carcinoma
Impact
- These are standard medical use layers. They can matter for enforcement strategy when composition is used with a specific clinical indication set.
Claims 19 and 20: explicit ^68Ga + ^18F combination
- Claim 19: M3+ is ^68Ga
- Claim 20: fluorine is ^18F and metal is ^68Ga
Impact
- Claim 20 is the most commercially pointed embodiment. It is a direct lock if any product employs ^18F-labeled Si-F radiohybrid agent and a ^68Ga chelation in the same formulation.
Claim-by-claim infringement relevance: where exposure concentrates
A. Formulation compliance is the first filter
To assess exposure quickly, the composition must satisfy all of the following from Claim 1:
| Parameter |
Claim 1 limits |
Dependent narrowing that often matches real products |
| pH |
4.0 to 6.0 |
Claim 4: 4.5 to 5.5 |
| Citrate buffer |
0.1 to 200 mM |
Claim 2: 1 to 15 mM; Claim 18: at least 10 mM pre-dilution |
| Ethanol |
1 to 100 mg/mL |
Claim 3: 5 to 50 mg/mL; Claim 12/14 exemplars |
| NaCl |
5 to 10 mg/mL |
Claim 14: 8.8 mg/mL (±10%) |
If a candidate formulation deviates materially from these windows, Claim 1 is likely not met. Conversely, if it matches, then the radiohybrid agent chemistry and labeling scenario become decisive.
B. Labeling architecture determines whether Claim 7-10 and Claim 19-20 apply
The radiohybrid agent must have:
- Si-F group, with ^18F or ^19F depending on the claim pathway, and/or
- chelated M3+, which may be radioactive or non-radioactive, with explicit positron-emitting status if radioactive.
Key “high signal” dependent targets:
- Claim 9: ^18F with non-radioactive M3+
- Claim 10: radioactive M3+ is a positron-emitting isotope
- Claim 19-20: M3+ = ^68Ga, and (in Claim 20) fluorine = ^18F
Scope summary: what the patent likely covers as a product class
What this patent covers
A US enforceable scope for:
- Radiohybrid imaging compositions using Si-F chemistry
- With a chelating group that binds M3+
- Formulated in an aqueous system with:
- citrate buffer in a wide band
- ethanol as a co-solvent
- low to mid single-digit NaCl mg/mL range
- acidic pH (4.0 to 6.0)
What it likely does not cover
- Compositions that do not include ethanol in the claimed mg/mL range
- Compositions outside pH 4.0 to 6.0
- Compositions that do not use citrate buffer (or are outside its claimed range)
- Compositions with NaCl outside 5 to 10 mg/mL
- Radiohybrid agents lacking a silicon-fluoride group or a chelating group satisfying M3+ definition
- Medical use of the composition outside cancer/neoangiogenesis/angiogenesis contexts in these use claims
Patent landscape implications for US enforcement strategy
1) Likely competitive design-around vectors
Based on the claim architecture, competitors typically target one of three layers:
Layer 1: formulation windows
- Shift pH above 6.0 or below 4.0
- Remove ethanol, or reduce ethanol below 1 mg/mL
- Change NaCl concentration below 5 mg/mL or above 10 mg/mL
- Eliminate citrate buffer or use a non-citrate buffer system
Layer 2: labeling scenario
- Use Si-F but not ^18F (and not within the dependent claim pathways)
- Use ^18F but do not include chelated M3+ consistent with the claims
- Use M3+ but not positron-emitting radionuclides when attempting to avoid Claim 10
Layer 3: pre-/post-dilution process
- Avoid the method that prepares citrate concentration at least 10 mM then dilutes with sodium chloride (Claim 18)
- Avoid dilution steps prior to administration (Claim 13)
2) Litigation risk concentrated in “anchored embodiments”
Claims 12 and 14 give explicit composition recipes that align with likely product prototypes:
- pH 5 with 10 mM citrate and 50 mg/mL ethanol and 7.2 mg/mL NaCl (Claim 12)
- diluted formulation with tight pH and citrate/ethanol/NaCl bands (Claim 14)
If a challenger’s product has equivalent composition, it becomes harder to argue outside Claim 1 because dependent claims indicate plausible real-world values sit within the claimed system.
3) Commercial risk highest for ^18F + ^68Ga
- Claim 20 ties together ^18F on Si-F and ^68Ga chelated via M3+
- Claim 19 locks ^68Ga presence if used
This combination is a natural focal point for competitor product roadmaps because ^18F and ^68Ga are common radiochemistry building blocks. Claim 20 turns that common pairing into a direct infringement attractor.
Key Takeaways
- Claim 1 is the main coverage vehicle: a Si-F radiohybrid agent with a chelating group plus strict formulation limits (pH 4.0-6.0, citrate 0.1-200 mM, ethanol 1-100 mg/mL, NaCl 5-10 mg/mL).
- Dependent claims narrow to specific formulation bands (pH 4.5-5.5, citrate 1-15 mM, ethanol 5-50 mg/mL), and include explicit exemplars (Claims 12 and 14) that can map to actual product recipes.
- Strong enforceability hooks include citrate preparation reagents (Claims 5-6), EOS RAC window (Claim 11), and process dilution with sodium chloride (Claims 13 and 18).
- Competitive exposure is highest for embodiments using ^18F and ^68Ga together (Claims 19-20) and for release/control conditions that fall within EOS 5-200 mCi/mL.
FAQs
1) What part of Claim 1 is most difficult to change via formulation reformulation?
The combined presence of citrate buffer, ethanol, and NaCl under specific concentration bands plus an acidic pH 4.0 to 6.0. Moving one parameter risks falling outside the pH or concentration windows.
2) Does the patent require ^18F specifically?
Not in Claim 1 as written. Claim 1 includes either ^18F on the silicon-fluoride group or a scenario where the chelating group contains a chelated radioactive metal. Specific embodiments are nailed down in dependent claims (e.g., Claim 9, Claim 20).
3) How do Claims 19 and 20 affect product development choices around metal radionuclides?
They create direct coverage for M3+ = ^68Ga (Claim 19) and the specific pairing of ^18F + ^68Ga (Claim 20). Products using these exact pairing conditions align tightly with the claim set.
4) Is the dilution step part of infringement risk?
Yes. Claim 13 covers diluting with sodium chloride solution prior to administration, and Claim 18 covers preparing at at least 10 mM citrate then diluting with sodium chloride. If the clinical dosing workflow includes these steps, infringement risk rises.
5) Do method-of-making claims matter if a competitor buys the composition?
Claims 18 (and the citrate preparation limitation in Claims 5-6) tie to manufacturing steps. Even if a competitor buys finished product, upstream manufacturing aligned to these steps can still trigger risk depending on enforcement posture.
References
[1] United States Patent 12,036,290. Claims 1-20 (as provided).
